• JULY 29, 2000

Disappointing results from Bayer

Bayer has reported disappointing results for the second quarter with the net level dropping 23% despite a 14.5% growth in the topline. The company has discontinued the marketing of pharma products with effect from July 27, 2000 which have been transferred to the parent's 100% subsidiary Bayer Pharmaceuticals. The company is to receive a consideration of Rs 70 m in lieu of the transfer.

(Rs m)2QFY992QFY00Change
Sales 1,558 1,784 14.5%
Other Income 17.1 14.1 -17.5%
Expenditure 1,414 1,635 15.7%
Operating Profit (EBDIT) 144 149 3.5%
Operating Profit Margin (%)9.2%8.3% 
Interest 69 75 9.3%
Depreciation 25 27 11.0%
Profit before Tax6861-10.4%
Other Adjustments - 2  
Tax 21 22 6.2%
Profit after Tax/(Loss) 47 37 -22.1%
Net profit margin (%)3.0%1.9% 
No. of Shares (eoy) (m) 16.2 16.2  
Diluted number of shares 16.2 16.2  
Diluted Earnings per share*11.69.1 

The stock quotes at Rs 619 implying an earning multiple of 68.7 times second quarter annualised earnings.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407